CDKN2A and familial melanoma: Taking into account the higher frequency of heterozygous CDKN2A deletions (36%) in melanoma specimens compared to homozygous losses (16%) [52], the relevance of the triple algorithm for predicting CDKN2A homozygous deletions in patients with MPM and familial melanoma, inapplicable to cases with heterozygous deletion, may be generated precisely by the variation in the incidence and clinical significance that the two different types of genetic alterations carry.